Liposomal Drug Delivery Systems for Targeted Cancer Therapy: Is Active Targeting the Best Choice?

References

• Siegel RL , MillerKD, JemalA. Cancer statistics, 2016. CA Cancer J. Clin.66 (1), 7–30 (2016).
   PubMed Web of Science ®Google Scholar
• Harding MC , SloanCD, MerrillRM, HardingTM, ThackerBJ, ThackerEL. Abstract MP67: transition from cardiovascular disease to cancer as the leading cause of death in US states, 1999–2013. Circulation133 (Suppl. 1), AMP67–AMP67 (2016).
   Google Scholar
• Pérez-Herrero E , Fernández-MedardeA. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm.93, 52–79 (2015).
   PubMed Web of Science ®Google Scholar
• Bertrand N , LerouxJ-C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Release161 (2), 152–163 (2012).
   PubMed Web of Science ®Google Scholar
• Jain RK , StylianopoulosT. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol.7 (11), 653–664 (2010).
   PubMed Web of Science ®Google Scholar
• Hrkach J , Von HoffD, AliMMet al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med.4 (128), 128ra139–128ra139 (2012).
   Web of Science ®Google Scholar
• Allen TM , CullisPR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev.65 (1), 36–48 (2013).
   PubMed Web of Science ®Google Scholar
• Patil YP , JadhavS. Novel methods for liposome preparation. Chem. Phys. Lipids177, 8–18 (2014).
   PubMed Web of Science ®Google Scholar
• Chang H-I , YehM-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed.7, 49 (2012).
   PubMed Web of Science ®Google Scholar
• Pattni BS , ChupinVV, TorchilinVP. New developments in liposomal drug delivery. Chem. Rev.115 (19), 10938–10966 (2015).
   PubMed Web of Science ®Google Scholar
• Alexis F , PridgenE, MolnarLK, FarokhzadOC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm.5 (4), 505–515 (2008).
   PubMed Web of Science ®Google Scholar
• Lian T , HoRJ. Trends and developments in liposome drug delivery systems. J. Pharm. Sci.90 (6), 667–680 (2001).
   PubMed Web of Science ®Google Scholar
• Hamann PR , HinmanLM, HollanderIet al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem.13 (1), 47–58 (2002).
   PubMed Web of Science ®Google Scholar
• Marcucci F , LefoulonF. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today9 (5), 219–228 (2004).
   PubMed Web of Science ®Google Scholar
• Çağdaş M , SezerAD, BucakS. Liposomes as potential drug carrier systems for drug delivery. Application of Nanotechnology in Drug Delivery. In : SezerAD ( Ed.). Intech, Rijeka, Croatia (2014).
   Google Scholar
• Matsumura Y , MaedaH. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res.46 (12 Part 1), 6387–6392 (1986).
   PubMed Web of Science ®Google Scholar
• Fang J , NakamuraH, MaedaH. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63 (3), 136–151 (2011).
   PubMed Web of Science ®Google Scholar
• Gabizon A , GorenD, HorowitzAT, TzemachD, LossosA, SiegalT. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev.24 (2), 337–344 (1997).
   Web of Science ®Google Scholar
• Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev.63 (3), 131–135 (2011).
   PubMed Web of Science ®Google Scholar
• Nagamitsu A , GreishK, MaedaH. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J. Clin. Oncol.39 (11), 756–766 (2009).
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N , FongeH, CaiZet al. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol. Pharm.9 (8), 2168–2179 (2012).
   PubMed Web of Science ®Google Scholar
• Noble GT , StefanickJF, AshleyJD, KiziltepeT, BilgicerB. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol.32 (1), 32–45 (2014).
   PubMed Web of Science ®Google Scholar
• Maruyama K . Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev.63 (3), 161–169 (2011).
   PubMed Web of Science ®Google Scholar
• Owens DE , PeppasNA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm.307 (1), 93–102 (2006).
   PubMed Web of Science ®Google Scholar
• Fan Y , ZhangQ. Development of liposomal formulations: from concept to clinical investigations. Asian J. Pharm. Sci.8 (2), 81–87 (2013).
   Google Scholar
• Dawidczyk CM , KimC, ParkJHet al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release187, 133–144 (2014).
   PubMed Web of Science ®Google Scholar
• Drummond DC , MeyerO, HongK, KirpotinDB, PapahadjopoulosD. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev.51 (4), 691–744 (1999).
   PubMed Web of Science ®Google Scholar
• Litzinger DC , BuitingAM, Van RooijenN, HuangL. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly (ethylene glycol)-containing liposomes. Biochim. Biophys. Acta1190 (1), 99–107 (1994).
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A , Rezaei-SadabadyR, DavaranSet al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett.8 (1), 102 (2013).
   PubMed Web of Science ®Google Scholar
• Cuomo F , MoscaM, MurgiaS, CeglieA, LopezF. Oligonucleotides and polynucleotides condensation onto liposome surface: effects of the base and of the nucleotide length. Colloids Surf. B Biointerfaces104, 239–244 (2013).
   PubMed Web of Science ®Google Scholar
• Miller CR , BondurantB, McleanSD, McgovernKA, O'brienDF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry37 (37), 12875–12883 (1998).
   PubMed Web of Science ®Google Scholar
• Levchenko TS , RammohanR, LukyanovAN, WhitemanKR, TorchilinVP. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm.240 (1), 95–102 (2002).
   PubMedGoogle Scholar
• Lasic D , MartinF, GabizonA, HuangS, PapahadjopoulosD. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta1070 (1), 187–192 (1991).
   PubMed Web of Science ®Google Scholar
• Tirosh O , BarenholzY, KatzhendlerJ, PrievA. Hydration of polyethylene glycol-grafted liposomes. Biophys. J.74 (3), 1371–1379 (1998).
   PubMed Web of Science ®Google Scholar
• Tan C , ZhangY, AbbasSet al. Biopolymer-lipid bilayer interaction modulates the physical properties of liposomes: mechanism and structure. J. Agric. Food Chem.63 (32), 7277–7285 (2015).
   PubMed Web of Science ®Google Scholar
• Sinico C , ManconiM, PeppiM, LaiF, ValentiD, FaddaAM. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J. Control. Release103 (1), 123–136 (2005).
   PubMed Web of Science ®Google Scholar
• Coderch L , FonollosaJ, De PeraM, EstelrichJ, De La MazaA, ParraJ. Influence of cholesterol on liposome fluidity by EPR: relationship with percutaneous absorption. J. Control. Release68 (1), 85–95 (2000).
   PubMed Web of Science ®Google Scholar
• Alam MI , PagetT, ElkordyAA. Formulation and advantages of furazolidone in liposomal drug delivery systems. Eur. J. Pharm. Sci.84, 139–145 (2016).
   PubMed Web of Science ®Google Scholar
• Gabizon A , PriceDC, HubertyJ, BresalierRS, PapahadjopoulosD. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res.50 (19), 6371–6378 (1990).
   PubMed Web of Science ®Google Scholar
• Lee C-M , ChoiY, HuhEJet al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother. Radiopharm.20 (6), 620–628 (2005).
   PubMed Web of Science ®Google Scholar
• Oussoren C , ZuidemaJ, CrommelinD, StormG. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta1328 (2), 261–272 (1997).
   PubMed Web of Science ®Google Scholar
• Allen T , HansenC, GuoL. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta1150 (1), 9–16 (1993).
   PubMed Web of Science ®Google Scholar
• Lu F , WuSH, HungY, MouCY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small5 (12), 1408–1413 (2009).
   PubMed Web of Science ®Google Scholar
• Lee KD , NirS, PapahadjopoulosD. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry32 (3), 889–899 (1993).
   PubMed Web of Science ®Google Scholar
• He C , HuY, YinL, TangC, YinC. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials31 (13), 3657–3666 (2010).
   PubMed Web of Science ®Google Scholar
• Andresen TL , JensenSS, J⊘rgensenK. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid Res.44 (1), 68–97 (2005).
   PubMed Web of Science ®Google Scholar
• Ishida T , KirchmeierM, MoaseE, ZalipskyS, AllenT. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta1515 (2), 144–158 (2001).
   PubMed Web of Science ®Google Scholar
• Connor J , YatvinMB, HuangL. pH-sensitive liposomes: acid-induced liposome fusion. Proc. Natl Acad. Sci. USA81 (6), 1715–1718 (1984).
   PubMed Web of Science ®Google Scholar
• Drummond DC , ZignaniM, LerouxJ-C. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res.39 (5), 409–460 (2000).
   PubMed Web of Science ®Google Scholar
• Luo D , CarterKA, RaziAet al. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials75, 193–202 (2016).
   PubMed Web of Science ®Google Scholar
• Morgan C , YianniY, SandhuS, MitchellA. Liposome fusion and lipid exchange on ultraviolet irradiation of liposomes containing a photochromic phospholipid. Photochem. Photobiol.62 (1), 24–29 (1995).
   PubMed Web of Science ®Google Scholar
• Yatvin MB , WeinsteinJN, DennisWH, BlumenthalR. Design of liposomes for enhanced local release of drugs by hyperthermia. Science202 (4374), 1290–1293 (1978).
   PubMed Web of Science ®Google Scholar
• Needham D , DewhirstMW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev.53 (3), 285–305 (2001).
   PubMed Web of Science ®Google Scholar
• Gaber MH , HongK, HuangSK, PapahadjopoulosD. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm. Res.12 (10), 1407–1416 (1995).
   PubMed Web of Science ®Google Scholar
• Lamparski H , LimanU, BarryJAet al. Photoinduced destabilization of liposomes. Biochemistry31 (3), 685–694 (1992).
   PubMed Web of Science ®Google Scholar
• Kirpotin D , HongK, MullahN, PapahadjopoulosD, ZalipskyS. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly (ethylene glycol). FEBS Lett.388 (2), 115–118 (1996).
   PubMed Web of Science ®Google Scholar
• Saito G , SwansonJA, LeeK-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev.55 (2), 199–215 (2003).
   PubMed Web of Science ®Google Scholar
• Duzgunes N , StraubingerR, BaldwinP, PapahadjopoulosD, WilschutJ, HoekstraD. pH-Sensitive Liposomes: Introduction of Foreign Substances into Cells. Marcel Dekker, NY, USA, 713–730 (1991).
   Google Scholar
• Cullis PT , KruijffBD. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta559 (4), 399–420 (1979).
   PubMedGoogle Scholar
• Simões S , MoreiraJN, FonsecaC, DüzgüneşN, De LimaMCP. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev.56 (7), 947–965 (2004).
   PubMed Web of Science ®Google Scholar
• Sudimack JJ , GuoW, TjarksW, LeeRJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta1564 (1), 31–37 (2002).
   PubMed Web of Science ®Google Scholar
• Subbarao NK , ParenteRA, SzokaFCJr, NadasdiL, PongraczK. The pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry26 (11), 2964–2972 (1987).
   PubMed Web of Science ®Google Scholar
• Legendre J-Y , SzokaFCJr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm. Res.9 (10), 1235–1242 (1992).
   PubMed Web of Science ®Google Scholar
• Ohkuma S , PooleB. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA75 (7), 3327–3331 (1978).
   PubMed Web of Science ®Google Scholar
• Fomina N , SankaranarayananJ, AlmutairiA. Photochemical mechanisms of light-triggered release from nanocarriers. Adv. Drug Deliv. Rev.64 (11), 1005–1020 (2012).
   PubMed Web of Science ®Google Scholar
• Bisby RH , MeadC, MorganCG. Active uptake of drugs into photosensitive liposomes and rapid release on UV photolysis. Photochem. Photobiol.72 (1), 57–61 (2000).
   PubMed Web of Science ®Google Scholar
• Kano K , TanakaY, OgawaT, ShimomuraM, OkahataY, KunitakeT. Photoresponsive membranes. Regulation of membrane properties by photoreversible cis-trans isomerization of azobenzenes. Chem. Lett.9 (4), 421–424 (1980).
   Google Scholar
• Regen SL , SinghA, OehmeG, SinghM. Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers. Biochem. Biophys. Res. Commun.101 (1), 131–136 (1981).
   PubMed Web of Science ®Google Scholar
• Yavlovich A , SinghA, BlumenthalR, PuriA. A novel class of photo-triggerable liposomes containing DPPC: DC 8, 9 PC as vehicles for delivery of doxorubcin to cells. Biochim. Biophys. Acta1808 (1), 117–126 (2011).
   PubMed Web of Science ®Google Scholar
• Kadri R , MessaoudGB, TamayolAet al. Preparation and characterization of nanofunctionalized alginate/methacrylated gelatin hybrid hydrogels. RSC Adv.6 (33), 27879–27884 (2016).
   Web of Science ®Google Scholar
• Anderson VC , ThompsonDH. Triggered release of hydrophilic agents from plasmologen liposomes using visible light or acid. Biochim. Biophys. Acta1109 (1), 33–42 (1992).
   PubMedGoogle Scholar
• Thompson DH , GerasimovOV, WheelerJJ, RuiY, AndersonVC. Triggerable plasmalogen liposomes: improvement of system efficiency. Biochim. Biophys. Acta1279 (1), 25–34 (1996).
   PubMed Web of Science ®Google Scholar
• Girotti AW . Photodynamic lipid peroxidation in biological systems. Photochem. Photobiol.51 (4), 497–509 (1990).
   PubMed Web of Science ®Google Scholar
• Weissleder R . A clearer vision for in vivo imaging. Nat. Biotechnol.19 (4), 316–317 (2001).
   PubMed Web of Science ®Google Scholar
• Prevo BG , EsakoffSA, MikhailovskyA, ZasadzinskiJA. Scalable routes to gold nanoshells with tunable sizes and response to near-infrared pulsed-laser irradiation. Small4 (8), 1183–1195 (2008).
   PubMed Web of Science ®Google Scholar
• Pashkovskaya A , KotovaE, ZorluYet al. Light-triggered liposomal release: membrane permeabilization by photodynamic action. Langmuir26 (8), 5726–5733 (2009).
   Web of Science ®Google Scholar
• Wu G , MikhailovskyA, KhantHA, FuC, ChiuW, ZasadzinskiJA. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc.130 (26), 8175–8177 (2008).
   PubMed Web of Science ®Google Scholar
• Dromi S , FrenkelV, LukAet al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res.13 (9), 2722–2727 (2007).
   PubMed Web of Science ®Google Scholar
• Anyarambhatla GR , NeedhamD. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome Res.9 (4), 491–506 (1999).
   Web of Science ®Google Scholar
• Li L , Ten HagenTL, SchipperDet al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J. Control. Release143 (2), 274–279 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholas AR , ScottMJ, KennedyNI, JonesMN. Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles. Biochim. Biophys. Acta1463 (1), 167–178 (2000).
   PubMed Web of Science ®Google Scholar
• Koning GA , EggermontAM, LindnerLH, Ten HagenTL. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm. Res.27 (8), 1750–1754 (2010).
   PubMed Web of Science ®Google Scholar
• Gaber MH , WuNZ, HongK, HuangSK, DewhirstMW, PapahadjopoulosD. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys.36 (5), 1177–1187 (1996).
   PubMed Web of Science ®Google Scholar
• Kong G , AnyarambhatlaG, PetrosWPet al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res.60 (24), 6950–6957 (2000).
   PubMed Web of Science ®Google Scholar
• Weinstein JN , MaginRL, CysykRL, ZaharkoDS. Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. Cancer Res.40 (5), 1388–1395 (1980).
   PubMed Web of Science ®Google Scholar
• Issels R , LindnerL, WendtnerCet al. 1LBA Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STS): results of the randomized EORTC-ESHO intergroup trial (NCI-00003052). Eur. J. Cancer Suppl.7 (3), 2 (2009).
   Google Scholar
• Barenholz Y . Liposome application: problems and prospects. Curr. Opin. Colloid Interface Sci.6 (1), 66–77 (2001).
   Web of Science ®Google Scholar
• Malam Y , LoizidouM, SeifalianAM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci.30 (11), 592–599 (2009).
   PubMed Web of Science ®Google Scholar
• Danhier F , FeronO, PréatV. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release148 (2), 135–146 (2010).
   PubMed Web of Science ®Google Scholar
• Rofstad EK , GalappathiK, MathiesenBS. Tumor interstitial fluid pressure – a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia16 (7), 586–594 (2014).
   PubMed Web of Science ®Google Scholar
• Lammers T , HenninkW, StormG. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer99 (3), 392–397 (2008).
   PubMed Web of Science ®Google Scholar
• Heldin C-H , RubinK, PietrasK, ÖstmanA. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer4 (10), 806–813 (2004).
   PubMed Web of Science ®Google Scholar
• Maeda H , SawaT, KonnoT. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release74 (1), 47–61 (2001).
   PubMed Web of Science ®Google Scholar
• Jain RK . Transport of molecules in the tumor interstitium: a review. Cancer Res.47 (12), 3039–3051 (1987).
   PubMed Web of Science ®Google Scholar
• Béduneau A , SaulnierP, BenoitJ-P. Active targeting of brain tumors using nanocarriers. Biomaterials28 (33), 4947–4967 (2007).
   PubMed Web of Science ®Google Scholar
• Weinstein JN , BlumenthalR, SharrowSO, HenkartPA. Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. Biochim. Biophys. Acta509 (2), 272–288 (1978).
   PubMedGoogle Scholar
• Chauhan VP , StylianopoulosT, BoucherY, JainRK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng.2, 281–298 (2011).
   PubMed Web of Science ®Google Scholar
• Byrne JD , BetancourtT, Brannon-PeppasL. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev.60 (15), 1615–1626 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng Z , Al ZakiA, HuiJZ, MuzykantovVR, TsourkasA. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science338 (6109), 903–910 (2012).
   PubMed Web of Science ®Google Scholar
• Kamaly N , XiaoZ, ValenciaPM, Radovic-MorenoAF, FarokhzadOC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev.41 (7), 2971–3010 (2012).
   PubMed Web of Science ®Google Scholar
• Peer D , KarpJM, HongS, FarokhzadOC, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2 (12), 751–760 (2007).
   PubMed Web of Science ®Google Scholar
• Shi J , XiaoZ, KamalyN, FarokhzadOC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res.44 (10), 1123–1134 (2011).
   PubMed Web of Science ®Google Scholar
• Kirpotin DB , DrummondDC, ShaoYet al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res.66 (13), 6732–6740 (2006).
   PubMed Web of Science ®Google Scholar
• Jeong Y , XieY, XiaoGet al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med.7 (12), e1000378 (2010).
   PubMed Web of Science ®Google Scholar
• Holbeck S , ChangJ, BestAM, BookoutAL, MangelsdorfDJ, MartinezED. Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor–drug and receptor–gene interactions. Mol. Endocrinol.24 (6), 1287–1296 (2010).
   PubMedGoogle Scholar
• Koshkaryev A , SawantR, DeshpandeM, TorchilinV. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv. Drug Deliv. Rev.65 (1), 24–35 (2013).
   PubMed Web of Science ®Google Scholar
• Srinivasarao M , GallifordCV, LowPS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discov.14 (3), 203–219 (2015).
   PubMed Web of Science ®Google Scholar
• Duncan R , VicentM, GrecoF, NicholsonR. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer12 (Suppl. 1), S189–S199 (2005).
   PubMedGoogle Scholar
• Bertrand N , WuJ, XuX, KamalyN, FarokhzadOC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev.66, 2–25 (2014).
   PubMed Web of Science ®Google Scholar
• Monopoli MP , ÅbergC, SalvatiA, DawsonKA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol.7 (12), 779–786 (2012).
   PubMed Web of Science ®Google Scholar
• Jiang W , KimBY, RutkaJT, ChanWC. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol.3 (3), 145–150 (2008).
   PubMed Web of Science ®Google Scholar
• Yu B , TaiHC, XueW, LeeLJ, LeeRJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol.27 (7), 286–298 (2010).
   PubMed Web of Science ®Google Scholar
• Saha RN , VasanthakumarS, BendeG, SnehalathaM. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol. Membr. Biol.27 (7), 215–231 (2010).
   PubMed Web of Science ®Google Scholar
• Reubi JC , SchonbrunnA. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol. Sci.34 (12), 676–688 (2013).
   PubMed Web of Science ®Google Scholar
• Kularatne SA , WangK, SanthapuramH-KR, LowPS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm.6 (3), 780–789 (2009).
   PubMedGoogle Scholar
• Lepenies B , LeeJ, SonkariaS. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv. Drug Deliv. Rev.65 (9), 1271–1281 (2013).
   PubMed Web of Science ®Google Scholar
• Yuan F , DellianM, FukumuraDet al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res.55 (17), 3752–3756 (1995).
   PubMed Web of Science ®Google Scholar
• Florence AT . “Targeting” nanoparticles: the constraints of physical laws and physical barriers. J. Control. Release164 (2), 115–124 (2012).
   PubMed Web of Science ®Google Scholar
• Pirollo KF , ChangEH. Does a targeting ligand influence nanoparticle tumor localization or uptake?Trends Biotechnol.26 (10), 552–558 (2008).
   PubMed Web of Science ®Google Scholar
• Maruyama K , IshidaO, TakizawaT, MoribeK. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev.40 (1), 89–102 (1999).
   PubMed Web of Science ®Google Scholar
• Cedervall T , LynchI, FoyMet al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. Engl.46 (30), 5754–5756 (2007).
   PubMed Web of Science ®Google Scholar
• Lundqvist M , StiglerJ, EliaG, LynchI, CedervallT, DawsonKA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA105 (38), 14265–14270 (2008).
   PubMed Web of Science ®Google Scholar
• Lammers T , KiesslingF, HenninkWE, StormG. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release161 (2), 175–187 (2012).
   PubMed Web of Science ®Google Scholar
• Choi CHJ , AlabiCA, WebsterP, DavisME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl Acad. Sci. USA107 (3), 1235–1240 (2010).
   PubMed Web of Science ®Google Scholar
• Nellis DF , GiardinaSL, JaniniGMet al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog.21 (1), 221–232 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki R , TakizawaT, KuwataYet al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm.346 (1), 143–150 (2008).
   PubMedGoogle Scholar
• Lu Y , LowPS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev.64, 342–352 (2012).
   Web of Science ®Google Scholar
• Sudimack J , LeeRJ. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev.41 (2), 147–162 (2000).
   PubMed Web of Science ®Google Scholar
• Antony AC . Folate receptors. Annu. Rev. Nutr.16 (1), 501–521 (1996).
   PubMedGoogle Scholar
• Reddy JA , HanelineLS, SrourEF, AntonyAC, ClappDW, LowPS. Expression and functional characterization of the β-isoform of the folate receptor on CD34+ cells. Blood93 (11), 3940–3948 (1999).
   PubMed Web of Science ®Google Scholar
• Lee RJ , LowPS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem.269 (5), 3198–3204 (1994).
   PubMed Web of Science ®Google Scholar
• Lu Y , LowPS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother.51 (3), 153–162 (2002).
   PubMed Web of Science ®Google Scholar
• Siegel BA , DehdashtiF, MutchDGet al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med.44 (5), 700–707 (2003).
   PubMed Web of Science ®Google Scholar
• Wang S , LuoJ, LantripDAet al. Design and synthesis of [111In] DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug. Chem.8 (5), 673–679 (1997).
   PubMed Web of Science ®Google Scholar
• Werner ME , KarveS, SukumarRet al. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials32 (33), 8548–8554 (2011).
   PubMed Web of Science ®Google Scholar
• Low PS , KularatneSA. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol.13 (3), 256–262 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao X , LiH, LeeRJ. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv.5 (3), 309–319 (2008).
   PubMed Web of Science ®Google Scholar
• Salazar MDA , RatnamM. The folate receptor: what does it promise in tissue-targeted therapeutics?Cancer Metastasis Rev.26 (1), 141–152 (2007).
   PubMed Web of Science ®Google Scholar
• Weitman SD , LarkRH, ConeyLRet al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res.52 (12), 3396–3401 (1992).
   PubMed Web of Science ®Google Scholar
• Nakashima-Matsushita N , HommaT, YuSet al. Selective expression of folate receptor and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum.42, 1609–1616 (1999).
   PubMed Web of Science ®Google Scholar
• Galluzzi L , MorselliE, KeppOet al. Mitochondrial gateways to cancer. Mol. Aspects Med.31 (1), 1–20 (2010).
   PubMed Web of Science ®Google Scholar
• Guzman-Villanueva D , MendiolaMR, NguyenHX, WeissigV. Influence of triphenylphosphonium (TPP) cation hydrophobization with phospholipids on cellular toxicity and mitochondrial selectivity (2015). www.symbiosisonlinepublishing.com/pharmacy-pharmaceuticalsciences/pharmacy-pharmaceuticalsciences21.pdf.
   Google Scholar
• Fulda S , GalluzziL, KroemerG. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov.9 (6), 447–464 (2010).
   PubMed Web of Science ®Google Scholar
• Smith RA , PorteousCM, GaneAM, MurphyMP. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl Acad. Sci. USA100 (9), 5407–5412 (2003).
   PubMed Web of Science ®Google Scholar
• Marrache S , DharS. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl Acad. Sci. USA109 (40), 16288–16293 (2012).
   PubMed Web of Science ®Google Scholar
• Pathak RK , KolishettiN, DharS. Targeted nanoparticles in mitochondrial medicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.7 (3), 315–329 (2015).
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T , JainRK. Design considerations for nanotherapeutics in oncology. Nanomedicine11 (8), 1893–1907 (2015).
   PubMed Web of Science ®Google Scholar
• Hillier SM , MarescaKP, FemiaFJet al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res.69 (17), 6932–6940 (2009).
   PubMed Web of Science ®Google Scholar
• Li X , YangW, ZouY, MengF, DengC, ZhongZ. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes. J. Control. Release220, 704–714 (2015).
   PubMed Web of Science ®Google Scholar
• Deng C , JiangY, ChengR, MengF, ZhongZ. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today7 (5), 467–480 (2012).
   Web of Science ®Google Scholar
• Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul.41 (1), 189–207 (2001).
   PubMedGoogle Scholar
• Allen TM . Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer2 (10), 750–763 (2002).
   PubMed Web of Science ®Google Scholar
• Pinheiro VB , TaylorAI, CozensCet al. Synthetic genetic polymers capable of heredity and evolution. Science336 (6079), 341–344 (2012).
   PubMed Web of Science ®Google Scholar
• Farokhzad OC , JonS, KhademhosseiniA, TranT-NT, LavanDA, LangerR. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells. Cancer Res.64 (21), 7668–7672 (2004).
   PubMed Web of Science ®Google Scholar
• Xiao Z , FarokhzadOC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano6 (5), 3670–3676 (2012).
   PubMed Web of Science ®Google Scholar
• Dubey PK , MishraV, JainS, MahorS, VyasS. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug Target.12 (5), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Colombo G , CurnisF, De MoriGMet al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem.277 (49), 47891–47897 (2002).
   PubMed Web of Science ®Google Scholar
• Negussie AH , MillerJL, ReddyG, DrakeSK, WoodBJ, DreherMR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J. Control. Release143 (2), 265–273 (2010).
   PubMed Web of Science ®Google Scholar
• Sakaguchi N , KojimaC, HaradaA, KoiwaiK, EmiN, KonoK. Effect of transferrin as a ligand of pH-sensitive fusogenic liposome−lipoplex hybrid complexes. Bioconjug. Chem.19 (8), 1588–1595 (2008).
   PubMed Web of Science ®Google Scholar
• Szwed M , MatusiakA, Laroche-ClaryA, RobertJ, MarszalekI, JozwiakZ. Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol. In Vitro28 (2), 187–197 (2014).
   PubMed Web of Science ®Google Scholar
• Joshee N , BastolaDR, ChengP-W. Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum. Gene Ther.13 (16), 1991–2004 (2002).
   PubMed Web of Science ®Google Scholar
• Alexis F , BastoP, Levy-NissenbaumEet al. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem3 (12), 1839–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Sandström M , LindskogK, VelikyanIet al. Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J. Nucl. Med.57 (6), 867–871 (2016).
   PubMed Web of Science ®Google Scholar
• Winkler J , Martin-KilliasP, PlückthunA, Zangemeister-WittkeU. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther.8 (9), 2674–2683 (2009).
   PubMed Web of Science ®Google Scholar
• Trzpis M , MclaughlinPM, De LeijLM, HarmsenMC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol.171 (2), 386–395 (2007).
   PubMed Web of Science ®Google Scholar
• Chari RV . Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev.31 (1), 89–104 (1998).
   PubMed Web of Science ®Google Scholar
• Glennie MJ , Van De WinkelJG. Renaissance of cancer therapeutic antibodies. Drug Discov. Today8 (11), 503–510 (2003).
   PubMed Web of Science ®Google Scholar
• Abou-Jawde R , ChoueiriT, AlemanyC, MekhailT. An overview of targeted treatments in cancer. Clin. Ther.25 (8), 2121–2137 (2003).
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L , BlanchetteJO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev.64, 206–212 (2012).
   Web of Science ®Google Scholar
• Leserman LD , BarbetJ, KourilskyF, WeinsteinJN. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature288 (5791), 602–604 (1980).
   PubMed Web of Science ®Google Scholar
• Bartlett DW , SuH, HildebrandtIJ, WeberWA, DavisME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA104 (39), 15549–15554 (2007).
   PubMed Web of Science ®Google Scholar
• Simard P , LerouxJ-C. In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen. Mol. Pharm.7 (4), 1098–1107 (2010).
   PubMedGoogle Scholar
• Anselmo AC , MitragotriS. Nanoparticles in the clinic. Bioeng. Transl. Med.1 (1), 10–29 (2016).
   PubMed Web of Science ®Google Scholar
• Munster PN , MillerK, KropIEet al. A Phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. Presented at : ASCO Annual Meeting. 1–5 June, Chicago, IL, USA (2012).
   Google Scholar
• Matsumura Y , GotohM, MuroKet al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol.15 (3), 517–525 (2004).
   PubMed Web of Science ®Google Scholar
• Albanese A , TangPS, ChanWC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng.14, 1–16 (2012).
   PubMed Web of Science ®Google Scholar
• Rodriguez PL , HaradaT, ChristianDA, PantanoDA, TsaiRK, DischerDE. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science339, 971–975 (2013).
   PubMed Web of Science ®Google Scholar
• Blanco E , ShenH, FerrariM. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotech.33, 941–951 (2015).
   PubMed Web of Science ®Google Scholar
• Ritz S , SchöttlerS, KotmanNet al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules16 (4), 1311–1321 (2015).
   PubMed Web of Science ®Google Scholar
• Nie S . Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine5 (4), 523–528 (2010).
   PubMed Web of Science ®Google Scholar